TechDigits

Tech news
Sunday, May 28, 2023

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration.
For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn't been able to get his diabetes medication.

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration, and is backordered at Anthony's Seattle pharmacy. 

Without the Novo Nordisk A/S-made prescription, he has suffered recurring dizzy spells while repairing cars. Alternative medications are either out of stock or not covered by his insurance.

While increased demand and supply chain delays have left multiple medicines from the antibiotic amoxicillin to Adderall in short supply, the reason for a lack of certain diabetes drugs is unusual: doctors are prescribing them to non-diabetics who want to use them for weight loss.

"All these famous people, stars who don't need to lose weight, are going and getting it," Mr Anthony said. "I need it to stay healthy and not die."

For the more than 35 million people who live with type 2 diabetes, the shortages have added yet another layer to managing an already complicated and costly chronic illness. They've also exposed weaknesses in America's use of off-label prescribing, which allows physicians to hand out drugs to treat a different condition than the one for which they were officially approved. When those medications are hard to find because of celebrity and social-media hype, patients with diabetes suffer.

Ozempic, known generically as semaglutide, is one of a class of diabetes drugs known as GLP-1 receptor agonists that have been around for nearly two decades. It was first approved in the US in 2017 for use in those with type 2 diabetes. Ozempic mimics a hormone involved in appetite and eating, helping to stimulate insulin production and lower patients' blood glucose levels. It also often leads to them shedding pounds.

Francisco Prieto, a family physician in Sacramento, California, sees at least one person with diabetes per week who is having trouble filling their prescription for Ozempic. Patients will call multiple pharmacies and drive around town to see if it's in stock, but some still haven't been able to get it, said Mr Prieto, who also does advocacy work for the American Diabetes Association.

Recently, one of Mr Prieto's patients experienced a three week-long delay filling a prescription for Trulicity, a similar type 2 diabetes drug that's also seeing increased demand for weight-loss use. Mr Prieto prescribed a lower dose, and recommended that the patient take two injections a week. He described the compromise as "less than ideal, but better than nothing."

Without their medication, patients with diabetes could be at higher risk for things like heart disease, heart attacks, infections like Covid, disability and even death, Mr Prieto said. And while getting a different prescription can be an option, it can come with new hurdles, including insurance coverage and closer monitoring in case the alternative doesn't work as well.

Both new and established users of Ozempic are being affected by periodic supply disruptions. A representative for manufacturer Novo Nordisk said in a statement that the issues are expected to continue through January. The company cited "incredible demand" and short-term capacity limitations at some factories, and said that it is investing to grow manufacturing.

Higher doses of Ozempic that aren't usually given to new patients are available, and Novo's other GLP-1 drugs for diabetes aren't in short supply, though there may be normal delays at pharmacies, the company said. In an earnings presentation in November, Novo said that its sales, as measured in Danish kroner, grew by 26% in the first nine months of the year, largely because of higher demand for Ozempic and other diabetes drugs.

Eli Lilly & Co.'s Trulicity and Mounjaro, both approved to treat type 2 diabetes, are also seeing demand that's resulting in backorders on some doses at pharmacies, a Lilly spokeswoman said. The drugs were listed as being in shortage by the FDA on Thursday. Lilly isn't having supply chain or manufacturing issues, though the company is working to double manufacturing capacity for the category by the end of next year, the spokeswoman said.

Though off-label prescribing is common and legal in the US, it has long created issues. In the early months of the Covid-19 pandemic, for example, people took an unproven drug called hydroxychloroquine, which they believed helped with the virus. That created shortages for patients who take it for lupus and arthritis.

Ozempic is a good candidate for off-label use for obesity, which is also considered a disease and can put people at higher risk for other conditions: official ads for the drug say patients lose on average up to 12 pounds when taking it. It's just not clear that everyone using the drug has a medical need for it.

On TikTok, some videos featuring the hashtag Ozempic have been viewed more than a million times. Medical spas offer the prescription alongside shots of Botox and laser hair removal. Sponsored ads on Google promise weight loss with no exercise or dieting. A plastic surgeon brags on Facebook about using the drug to lose 10 pounds she gained during Covid, and says to call her office to get started.

The FDA doesn't regulate this kind of prescribing. That means many decisions about what to do are up to individuals.

"Which disease is most acute and most severe? Which has alternatives? How adequate are those alternatives?" said Holly Fernandez Lynch, an assistant professor of medical ethics and law at the University of Pennsylvania. "These are the kinds of questions that would help you figure out which patients should have priority access."

Fernandez Lynch said a judgement would depend on the individual case. But those who just want to lose a few pounds shouldn't take a scarce resource that someone else needs, she said.

In Seattle, Mr Anthony has recently been able to get an alternative diabetes drug. It's a much older treatment that requires twice-a-day injections before mealtimes, which he didn't have to think about with Ozempic and has found challenging. It's too soon to know how well it will work for him.

Mr Prieto, the family physician, said his patients are scared and alarmed about the shortage - especially if the drug has really helped improve their health.

"Right now, diabetes is the greater danger, and those folks have a higher need for the drug," he said.
Newsletter

Related Articles

TechDigits
Close
0:00
0:00
TikTok Sues Montana Over Law Banning the App
Mobile phone giant Vodafone to cut 11,000 jobs globally over three years as new boss says its performance not good enough
Warren Buffett Sells TSMC Shares Over Concerns About Taiwan's Stability
'Godfather Of AI' Geoffrey Hinton Quits Google To Warn Of The Tech's Dangers
Vermont Man Charged with Stalking After Secretly Tracking Woman with Apple AirTag
Elon Musk Statements About Tesla Autopilot Could Be 'Deepfakes,' Lawyers Claim. Judge Evette Pennypacker Does Not Understand How Far and Advanced This Technology Became
AT&T's Successful Test of Satellite-Based Phone Call Raises Possibility of Widespread Coverage
Pulitzer Prize-winning journalist Seymour Hersh slams New York Times' pro-government stance and treatment of sources
Fox News Settles their case with Dominion Voting Systems for a staggering $787.5 MILLION
The G-7 aims to make global crypto regulations tougher
China and Brazil have signed a new deal that will allow them to trade in their own currencies, bypassing the US dollar as an intermediary
Elon Musk and Others Call for Pause on A.I., Citing ‘Profound Risks to Society’
U.S. charges FTX's Bankman-Fried with paying $40 million bribe
Fallen 'Crypto King' Who Owes Millions to Investors Was Kidnapped and Tortured
Regulators blame social media for SVB's rapid collapse: 'Complete game changer'
AOC explains why she opposes banning TikTok
Gordon Moore, a co-founder of Intel Corporation, died at 94
Donald Trump arrested – Twitter goes wild with doctored pictures
Credit Suisse's Scandalous History Resulted in an Obvious Collapse - It's time for regulators who fail to do their job to be held accountable and serve as an example by being behind bars.
Russian Hackers Preparing New Cyber Assault Against Ukraine
A brief banking situation report
Elon Musk Is Planning To Build A Town In Texas For His Employees
The Silicon Valley Bank’s collapse effect is spreading around the world, affecting startup companies across the globe
Market Chaos as USDC Loses Peg to USD after $3.3 Billion Reserves Held by Silicon Valley Bank Closed.
Banking regulators close SVB, the largest bank failure since the financial crisis
In a major snub to Downing Street's Silicon Valley dreams, UK chip giant Arm has dealt a serious blow to the government's economic strategy by opting for a US listing
It's the question on everyone's lips: could a four-day workweek be the future of employment?
Corruption and Influence Buying Uncovered in International Mainstream Media: Investigation Reveals Growing Disinformation Mercenaries
Being a Tiktoker might be expensive…
China's top tech firms, including Alibaba, Tencent, Baidu, NetEase, and JD.com, are developing their own versions of Open AI's AI-powered chatbot, ChatGPT
This shocking picture, showing how terrible is the results of the earthquake in Turkey
The desk of King Carlos Alberto of Sardinia has many secret compartments
Charlie Munger, calls for a ban on cryptocurrencies in the US, following China's lead
First generation unopened iPhone set to fetch more than $50,000 at auction.
Almost 30% of professionals say they've tried ChatGPT at work
Interpol seeks woman who ran elaborate exam cheating scam in Singapore
What is ChatGPT?
Tesla reported record profits and record revenues for 2022
Microsoft is finalising plans to become the latest technology giant to reduce its workforce during a global economic slowdown
Tesla slashes prices globally by as much as 20 percent
After Failing To Pay Office Rent, Twitter May Sell User Names
FTX fraud investigators are digging deeper into Sam Bankman-Fried's inner circle – and reportedly have ex-engineer Nishad Singh in their sights
TikTok CEO Plans to Meet European Union Regulators
U.S. Moves to Seize Robinhood Shares, Silvergate Accounts Tied to FTX
Coinbase to Pay $100 Million in Settlement With New York Regulator
FTX assets worth $3.5bn held by Bahamas securities regulator
Former FTX CEO Bankman-Fried finally arrested in Bahamas after U.S. files charges
Corruption works: House Financial Services Chair Waters doesn't plan to subpoena her donor, Sam Bankman-Fried, to testify at hearing on FTX collapse
Yellen hints at ‘national security’ probe into Twitter purchase
Elon Musk reinstates Donald Trump's Twitter account.
×